Sera Prognostics Appoints Myriad Ex-CEO to Drive PreTRM Test Adoption
SERA•Sera Prognostics appointed Mark Capone, former CEO of Myriad Genetics with 40 years of diagnostics leadership, to its board effective July 1, 2026. His expertise in commercializing molecular diagnostics and navigating reimbursement environments aims to accelerate adoption of the PreTRM test and support the company’s growth.
1. Board Appointment
On July 1, 2026, Sera Prognostics named Mark Capone to its board of directors, bolstering its governance with a seasoned diagnostics executive. This addition reflects the company’s focus on leveraging high-level leadership to advance its commercial and strategic objectives.
2. Mark Capone’s Experience
Capone brings over 40 years of leadership across diagnostics and life sciences, including a 17-year tenure at Myriad Genetics where he served as COO, President and CEO. He led Myriad’s transformation into a precision medicine organization, expanded its molecular diagnostics portfolio and strengthened its commercial execution.
3. Strategic Growth Implications
Capone’s proven track record in product commercialization, reimbursement strategy and payer engagement is expected to support wider adoption of the PreTRM test. His insights into scaling diagnostic platforms align with Sera Prognostics’ aim to drive long-term growth and enhance maternal and neonatal health outcomes.
